Sec Form 4 Filing - Singer Andrew E. @ Epizyme, Inc. - 2016-07-11

Insider filing report for Changes in Beneficial Ownership
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
FORM 4
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Expires: November 30, 2011
Estimated average burden hours per response... 0.5
1. Name and Address of Reporting Person
Singer Andrew E.
2. Issuer Name and Ticker or Trading Symbol
Epizyme, Inc. [ EPZM]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
_____ Director _____ 10% Owner
X __ Officer (give title below) _____ Other (specify below)
EVP & CFO
(Last) (First) (Middle)
C/O EPIZYME, INC., 400 TECHNOLOGY SQUARE
3. Date of Earliest Transaction (MM/DD/YY)
07/11/2016
(Street)
CAMBRIDGE, MA02139
4. If Amendment, Date Original Filed (MM/DD/YY)
6. Individual or Joint/Group Filing (Check Applicable Line)
__ X __ Form filed by One Reporting Person
_____ Form filed by More than One Reporting Person
(City) (State) (Zip)
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3)
2. Transaction Date (MM/DD/YY) 2A. Deemed Execution Date, if any (MM/DD/YY) 3. Transaction Code
(Instr. 8)
4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4)
6. Ownership Form: Direct (D) or Indirect (I)
(Instr. 4)
7. Nature of Indirect Beneficial Ownership
(Instr. 4)
Code V Amount (A) or (D) Price
Common Stock, par value $0.0001 07/11/2016 M 1,682 A 24,828 D
Common Stock, par value $0.0001 07/11/2016 M 777 A 25,605 D
Common Stock, par value $0.0001 07/11/2016 S( 2 ) 1,013 D $ 10.3593 ( 3 ) 24,592 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
( e.g. , puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security
(Instr. 3)
2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (MM/DD/YY) 3A. Deemed Execution Date, if any (MM/DD/YY) 4. Transaction Code
(Instr. 8)
5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4, and 5)
6. Date Exercisable and Expiration Date
(MM/DD/YY)
7. Title and Amount of Underlying Securities
(Instr. 3 and 4)
8. Price of Derivative Security
(Instr. 5)
9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 4)
10. Ownership Form of Derivative Security: Direct (D) or Indirect (I)
(Instr. 4)
11. Nature of Indirect Beneficial Ownership
(Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Restricted Stock Units ( 1 ) 07/11/2016 M 1,682 ( 4 ) ( 4 ) Common Stock 1,682 $ 0 52,139 D
Restricted Stock Units ( 1 ) 07/11/2016 M 777 ( 5 ) ( 5 ) Common Stock 777 $ 0 24,098 D
Reporting Owners
Reporting Owner Name / Address Relationships
Director 10% Owner Officer Other
Singer Andrew E.
C/O EPIZYME, INC.
400 TECHNOLOGY SQUARE
CAMBRIDGE, MA02139
EVP & CFO
Signatures
/s/ Adriana Sullivan, attorney-in-fact 07/13/2016
Signature of Reporting Person Date
Explanation of Responses:
( 1 )Each restricted stock unit represents the contingent right to receive one share of Epizyme, Inc. common stock upon vesting.
( 2 )The sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person to cover taxes associated with the vesting of his restricted stock.
( 3 )The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $10.26 per share to $10.47 per share, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
( 4 )This award, granted on February 9, 2016, pursuant to the reporting person's employment agreement, dated January 23,2015, vests as to 25% of the total award on February 9, 2016, a year from the commencement of employment, with the remaining 75% vesting in 36 substantially equal monthly installments thereafter. Vested shares will be delivered to the reporting person.
( 5 )This award, granted on February 9, 2015, pursuant to the Company's 2013 Stock Inventive Plan, vests as to 25% of the total award on February 9, 2016, with the remaining 75% vesting in 36 substantially equal monthly installments thereafter. Vested shares will be delivered to the reporting person.

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.